[Evaluation of megestrol acetate as monotherapy in disseminated prostatic carcinoma].
OBJECTIVE
To determine the effects of megestrol acetate on testosterone, dehydroepiandrosterone and PSA levels in patients with disseminated prostatic carcinoma.


METHODS
26 patients with disseminated prostatic carcinoma treated with megestrol acetate were followed for 21 months to determine its effects on testosterone, dehydroepiandrosterone and PSA levels.


CONCLUSIONS
We observed a testicular and adrenal antiandrogenic effect. Patient clinical course improved when PSA levels dropped, although this improvement was not related with changes in androgen levels.
Gallo Rolania
F J
FJ
Servicio de Urología, Hospital de León, España.
D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D019290:Megestrol Acetate / Q000627:therapeutic use*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D013739:Testosterone / Q000097:blood
D018931:Antineoplastic Agents, Hormonal; D013739:Testosterone; D017430:Prostate-Specific Antigen; D019290:Megestrol Acetate
Valoración del Megestrol Acetato como monoterapia en el carcinoma prostático diseminado.